Finance

Lists
Why is KROS up 4,52%?
Dive Deeper
KROS:NASDAQ
Keros Therapeutics Inc
11,56 USD
+4,52%
(+0,50) 1D
20-окт., 13:41:20 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KROS...
Open
11,04 USD
High
11,66 USD
Low
11,04 USD
Mkt. cap
229,20 млн
Avg. vol.
189,44 миң
Volume
55,50 миң
52-wk high
22,55 USD
52-wk low
9,69 USD
EPS
-3,70 USD
Beta
1,12
Shares outstanding
19,83 млн
No. of employees
92
Open
11,04 USD
High
11,66 USD
Low
11,04 USD
Mkt. cap
229,20 млн
Avg. vol.
189,44 миң
Volume
55,50 миң
52-wk high
22,55 USD
52-wk low
9,69 USD
EPS
-3,70 USD
Beta
1,12
Shares outstanding
19,83 млн
No. of employees
92
News stories
From web sources and news partners
About Keros Therapeutics Inc
CEO-
Employees92
Founded2015
HeadquartersЛексингтон, Массачусетс, Америка Кошмо Штаттары
Sector-
Websitekerostx.com
Analyst ratings
Based on 6 analysts giving stock ratings to KROS in the past 3 months
Buy
Buy
3
Hold
3
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KROS in the last 3 months.
Highest
Current 11,56 USD
23,00 USD (+98,96%)
Average
18,80 USD (+62,63%)
Lowest
16,00 USD (+38,41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Benjamin Burnett
Wells Fargo
Buy
Maintained
18,00 USD
+55,7%
09/02/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
17,00 USD
+47,1%
08/11/2026
Yun Zhong
Wedbush
Hold
Maintained
16,00 USD
+38,4%
08/04/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
20,00 USD
+73%
08/04/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/04/2026
Thomas Smith
Leerink Partners
Buy
Maintained
23,00 USD
+99%
08/04/2026
Nicholas Lorusso
TD Cowen
Hold
Reiterated
-
-
08/04/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/15/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
27,00 USD
+133,6%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
30,00 USD
+159,5%
03/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
20,00 USD
+73%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
14,26 млн
385,00 миң
367,00 миң
-
Cost of goods sold
19,52 млн
17,81 млн
16,10 млн
22,33 млн
Cost of revenue
19,52 млн
17,81 млн
16,10 млн
22,33 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,13 млн
11,74 млн
10,15 млн
8,61 млн
Operating expense
10,13 млн
11,74 млн
10,15 млн
8,61 млн
Total operating expenses
29,65 млн
29,56 млн
26,24 млн
30,94 млн
Operating income
-15,38 млн
-29,17 млн
-25,88 млн
-30,94 млн
Other non operating income
-
-539,00 миң
-
-60,00 миң
EBT including unusual items
-8,70 млн
-24,98 млн
-23,71 млн
-28,71 млн
EBT excluding unusual items
-8,70 млн
-24,88 млн
-23,71 млн
-28,71 млн
Income tax expense
-1,42 млн
-1,51 млн
-
-
Effective tax rate
16,36%
6,06%
-
-
Other operating expenses
-
-
-
-
Net income
-7,28 млн
-23,46 млн
-23,71 млн
-28,71 млн
Net profit margin
-51,04%
-6 093,77%
-6 459,95%
-
Earnings per share
-0,18
-0,86
-1,21
-1,45
Interest and investment income
6,93 млн
4,02 млн
2,34 млн
2,29 млн
Interest expense
-
-
-
-
Net interest expenses
6,93 млн
4,02 млн
2,34 млн
2,29 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-14,99 млн
-28,77 млн
-25,47 млн
-30,54 млн
Gain or loss from assets sale
-
1,00 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору